Leroy Pacheco, MD
Rheumatology · Albuquerque, NMNPI 1568438752
Payments from drug & device makers
Across 530 payments — averaging $4618.00 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- UCB SA$1.1M
- Eli Lilly$430K
- AbbVie$294K
- Janssen Research & Development, LLC$199K
- Novartis$122K
- Biogen$87K
- plus $250K from 31 others
Across 26 payments — averaging $222.34 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Eli Lilly$2K
- Gilead$2K
- GSK$1K
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| UCB SA | 44 | $1,065,699 |
| Eli Lilly | 31 | $430,138 |
| AbbVie | 96 | $293,753 |
| Janssen Research & Development, LLC | 39 | $198,878 |
| Novartis | 16 | $122,077 |
| Biogen | 2 | $86,843 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 1 | $72,650 |
| GSK | 27 | $44,150 |
| Amgen(2 entities) | 43 | $41,932 |
| E.r. Squibb & Sons, L.L.C. | 19 | $40,071 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $19,344 |
| Roche Products Limited | 3 | $11,873 |
| Gilead | 5 | $6,587 |
| Boehringer Ingelheim | 9 | $4,666 |
| Sandoz | 1 | $2,933 |
| UCB Biosciences Inc. | 9 | $1,986 |
| UCB, Inc. | 32 | $788 |
| Johnson & Johnson | 31 | $640 |
| AstraZeneca(2 entities) | 28 | $512 |
| Noven Pharmaceuticals, Inc. | 7 | $420 |
| Genentech USA, Inc. | 31 | $327 |
| Sobi, Inc | 9 | $245 |
| Sanofi-aventis U.S. LLC | 4 | $201 |
| Lilly USA, LLC | 9 | $176 |
| Pfizer | 9 | $154 |
| Organon | 4 | $113 |
| Aurinia Pharma U.S., Inc. | 4 | $84 |
| Sanofi | 3 | $72 |
| Kyowa Kirin, Inc. | 2 | $57 |
| Mallinckrodt Hospital Products Inc. | 2 | $31 |
| Pacira Therapeutics, Inc. | 1 | $24 |
| Bristol Myers Squibb | 1 | $24 |
| Regeneron Healthcare Solutions, Inc. | 1 | $22 |
| Radius Health, Inc. | 1 | $20 |
| Pacira Pharmaceuticals Incorporated | 1 | $20 |
| Merck | 1 | $16 |
| Teva Pharmaceuticals USA, Inc. | 1 | $13 |
How this compares
$2,447,541 in reported general payments places this provider in the 95th percentile of 44 rheumatology providers in New Mexico.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other rheumatology in Albuquerque
- Wilmer SibbittAlbuquerque$46K
- Albert RizzoliAlbuquerque$7K
- Scott StoernerAlbuquerque$5K
- Andres PeisajovichAlbuquerque$4K
- Sabeen YaqubAlbuquerque$4K
- Mirza BegAlbuquerque$4K
- Ahsan IqbalAlbuquerque$3K
- Peter RosandichAlbuquerque$2K
- Juliet CoquiaAlbuquerque$2K
- Jacqueline DeanAlbuquerque$2K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.